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1. INTRODUCTION {#ags312233-sec-0001}
===============

Anatomical liver resection (AR) is believed to reduce the risk of intrahepatic metastases and recurrences attributable to the invasion of tumor cells in the nearby portal veins.[1](#ags312233-bib-0001){ref-type="ref"}, [2](#ags312233-bib-0002){ref-type="ref"}, [3](#ags312233-bib-0003){ref-type="ref"}, [4](#ags312233-bib-0004){ref-type="ref"}, [5](#ags312233-bib-0005){ref-type="ref"} Some studies have reported the benefits of AR compared with non‐anatomical liver resection (NAR),[6](#ags312233-bib-0006){ref-type="ref"}, [7](#ags312233-bib-0007){ref-type="ref"}, [8](#ags312233-bib-0008){ref-type="ref"}, [9](#ags312233-bib-0009){ref-type="ref"}, [10](#ags312233-bib-0010){ref-type="ref"}, [11](#ags312233-bib-0011){ref-type="ref"} but other research has failed to confirm the same results.[12](#ags312233-bib-0012){ref-type="ref"}, [13](#ags312233-bib-0013){ref-type="ref"}, [14](#ags312233-bib-0014){ref-type="ref"}, [15](#ags312233-bib-0015){ref-type="ref"} Which category of patients is most effectively treated by AR thus remains controversial.

Laparoscopic liver resection became widespread in the 1990s and is now in common use. At first, this surgery was considered controversial, but constant improvements have been made in the procedure, techniques and surrounding materials such as energy devices, forceps and scopes. As a result, laparoscopic liver resection is now one of the standard options for liver malignancies, showing merits in the operation fields and degree of invasiveness. Recently, laparoscopic liver resection has shown superiority in terms of lower intraoperative blood loss, shorter length of hospital stay and same overall and disease‐free survival compared to open liver resection.[16](#ags312233-bib-0016){ref-type="ref"}, [17](#ags312233-bib-0017){ref-type="ref"}, [18](#ags312233-bib-0018){ref-type="ref"}, [19](#ags312233-bib-0019){ref-type="ref"}, [20](#ags312233-bib-0020){ref-type="ref"}, [21](#ags312233-bib-0021){ref-type="ref"}, [22](#ags312233-bib-0022){ref-type="ref"} However, the underlying pathologies are heterogeneous, and previous studies have included small numbers of participants and differing complication rates.[23](#ags312233-bib-0023){ref-type="ref"}, [24](#ags312233-bib-0024){ref-type="ref"}, [25](#ags312233-bib-0025){ref-type="ref"}, [26](#ags312233-bib-0026){ref-type="ref"}, [27](#ags312233-bib-0027){ref-type="ref"} Recently, results from the first randomized controlled trial (RCT) and some large cohort studies have become available.[28](#ags312233-bib-0028){ref-type="ref"} Thus, more robust evidence with which to carry out laparoscopic liver resection as a standard treatment is now available.

Over the last two decades, patients with colorectal liver metastases (CRM) have shown marked improvements in long‐term survival thanks to advances in chemotherapy and surgical techniques.[29](#ags312233-bib-0029){ref-type="ref"} However, the use of several cytotoxic agents has been associated with specific liver injuries.[30](#ags312233-bib-0030){ref-type="ref"}, [31](#ags312233-bib-0031){ref-type="ref"}, [32](#ags312233-bib-0032){ref-type="ref"}, [33](#ags312233-bib-0033){ref-type="ref"} A deeper understanding of the mechanisms of action and side‐effects of common agents is needed to achieve maximal oncological benefit while reducing adverse effects from CRM.

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a novel procedure to maximize remnant liver volume to carry out extended right liver resection such as right trisegmentectomy.[34](#ags312233-bib-0034){ref-type="ref"} However, according to the international ALPPS registry, more than 15% of ALPPS were done in patients who may have had no indications for two‐stage hepatectomy.[35](#ags312233-bib-0035){ref-type="ref"} They cautioned against overuse of ALPPS and mentioned that the indications should be carefully considered. The indications for ALPPS should thus be reconsidered to balance safety and efficacy. To overcome the high morbidity after ALPPS, a modified procedure is now available.[36](#ags312233-bib-0036){ref-type="ref"}, [37](#ags312233-bib-0037){ref-type="ref"}, [38](#ags312233-bib-0038){ref-type="ref"}, [39](#ags312233-bib-0039){ref-type="ref"}

2. ANATOMICAL LIVER RESECTION IN HEPATOCELLULAR CARCINOMA {#ags312233-sec-0002}
=========================================================

The concept of AR was proposed in the 1930s as a right or left hepatectomy.[40](#ags312233-bib-0040){ref-type="ref"} Thereafter, in 1985, Makuuchi described ultrasonically anatomical subsegmentectomy for hepatocellular carcinoma (HCC) in which every Couinaud\'s segment could be completely removed.[1](#ags312233-bib-0001){ref-type="ref"} The 5‐year survival rate was better in the AR group (35%) than in the enucleation group (66%, *P* \< 0.05). As a result, AR was considered theoretically effective for avoiding intrahepatic metastasis of cancer cells through the portal vein, with a preference for eradicating portal venous tumor extension in HCC. In contrast, AR requires the sacrifice of a large amount of liver parenchyma to guarantee eradication of potential vascular invasion and tumor spread through the portal vein. Some authors have described AR as too complex and offering no contribution to survival.[41](#ags312233-bib-0041){ref-type="ref"}, [42](#ags312233-bib-0042){ref-type="ref"}, [43](#ags312233-bib-0043){ref-type="ref"} Most previous studies have shown no clear evidence regarding the superiority of AR and some meta‐analyses have also reported conflicting results.[12](#ags312233-bib-0012){ref-type="ref"}, [13](#ags312233-bib-0013){ref-type="ref"}, [14](#ags312233-bib-0014){ref-type="ref"}, [15](#ags312233-bib-0015){ref-type="ref"}

The current series represents a review of AR between 2001 and 2015 (Table [1](#ags312233-tbl-0001){ref-type="table"}). We identified 18 studies on the surgical treatment of single lesions \<5 cm in diameter. Most of these papers (13 studies) were retrospective,[2](#ags312233-bib-0002){ref-type="ref"}, [3](#ags312233-bib-0003){ref-type="ref"}, [4](#ags312233-bib-0004){ref-type="ref"}, [5](#ags312233-bib-0005){ref-type="ref"}, [6](#ags312233-bib-0006){ref-type="ref"}, [7](#ags312233-bib-0007){ref-type="ref"}, [8](#ags312233-bib-0008){ref-type="ref"}, [9](#ags312233-bib-0009){ref-type="ref"}, [10](#ags312233-bib-0010){ref-type="ref"} with four matched cohorts[13](#ags312233-bib-0013){ref-type="ref"}, [41](#ags312233-bib-0041){ref-type="ref"}, [42](#ags312233-bib-0042){ref-type="ref"}, [43](#ags312233-bib-0043){ref-type="ref"} and one national survey from Japan.[12](#ags312233-bib-0012){ref-type="ref"} Sufficient number of participants was included in each study. Morbidity rate ranged from 8% to 46% with AR and from 4.8% to 42% with NAR. No obvious difference in morbidity was seen between the two procedures. At the same time, mortality associated with liver resection has improved dramatically over the last two decades, implying that significant differences may not exist between procedures.[15](#ags312233-bib-0015){ref-type="ref"}

###### 

Anatomical versus non‐anatomical liver resection

         First author   Year                                                 Term        Study type        Patients   Procedure    Tumor size (cm)                                      Single tumor (%)   Morbidity (%)   Mortality (%)   5‐y survival (%)   Reference no.
  ------ -------------- ---------------------------------------------------- ----------- ----------------- ---------- ------------ ---------------------------------------------------- ------------------ --------------- --------------- ------------------ -------------------------------------------
  1      Yamamoto       2001                                                 1990‐1994   Retrospective     90         AR           2.7 (±1.0)[a](#ags312233-note-0003){ref-type="fn"}   95.1               N.A.            1.1             67                 [14](#ags312233-bib-0014){ref-type="ref"}
  114    NAR            2.5 (±1.0)[a](#ags312233-note-0003){ref-type="fn"}   96.4        N.A.              2.6        55.8                                                                                                                                    
  2      Hasegawa       2005                                                 1994‐2001   Retrospective     156        AR           3.5 (1.2‐20.5)                                       100                N.A.            0               66                 [44](#ags312233-bib-0044){ref-type="ref"}
  54     NAR            3 (1.2‐170)                                          100         N.A.              0          35                                                                                                                                      
  3      Capussotti     2005                                                 1985‐2001   Retrospective     164        AR           5.1[a](#ags312233-note-0003){ref-type="fn"}          N.A.               37.2            N.A.            33.9               [6](#ags312233-bib-0006){ref-type="ref"}
  52     NAR            4.2[a](#ags312233-note-0003){ref-type="fn"}          N.A.        38.5              N.A.       39.3                                                                                                                                    
  4      Kaibori        2006                                                 1992‐2003   Retrospective     34         AR           4.1 (±2.1)[a](#ags312233-note-0003){ref-type="fn"}   64.7               23.5            2.9             52.7               [7](#ags312233-bib-0007){ref-type="ref"}
  213    NAR            3.3 (±2.3)[a](#ags312233-note-0003){ref-type="fn"}   72.7        25.8              1.9        46.2                                                                                                                                    
  5      Wakai          2007                                                 1990‐2004   Retrospective     95         AR           3.5 (1.2‐17.0)                                       100                22              2               67                 [8](#ags312233-bib-0008){ref-type="ref"}
  63     NAR            3.0 (1.0‐12.0)                                       100         25                6          59                                                                                                                                      
  6      Yamashita      2007                                                 1985‐2004   Retrospective     201        AR           2.9 (±0.1)[a](#ags312233-note-0003){ref-type="fn"}   100                8               N.A.            76                 [9](#ags312233-bib-0009){ref-type="ref"}
  120    NAR            2.4 (±0.1)[a](#ags312233-note-0003){ref-type="fn"}   100         10.8              N.A.       74                                                                                                                                      
  7      Cho            2007                                                 1998‐2001   Retrospective     99         AR           3.5[a](#ags312233-note-0003){ref-type="fn"}          100                12.1            0.7             65.7               [10](#ags312233-bib-0010){ref-type="ref"}
  69     NAR            3.1[a](#ags312233-note-0003){ref-type="fn"}          100         20.3              0.8        49.3                                                                                                                                    
  8      Eguchi         2008                                                 1994‐2001   National survey   2267       AR           3.1                                                  100                N.A.            0.71            65.5               [12](#ags312233-bib-0012){ref-type="ref"}
  3514   NAR            2.8                                                  100         N.A.              0.86       62.4                                                                                                                                    
  9      Kobayashi      2008                                                 1990‐2004   Retrospective     106        AR           3.0 (1.1‐14.0)                                       100                17              0               54                 [11](#ags312233-bib-0011){ref-type="ref"}
  127    NAR            2.8 (1.0‐14.5)                                       100         21                0          61                                                                                                                                      
  10     Dahiya         2010                                                 1983‐2002   Retrospective     159        AR           N.A.                                                 N.A.               46              1.8             47.5               [45](#ags312233-bib-0045){ref-type="ref"}
  214    NAR            N.A.                                                 N.A.        42                0          49.4                                                                                                                                    
  11     Kamiyama       2010                                                 1990‐2006   Retrospective     169        AR           3.1[a](#ags312233-note-0003){ref-type="fn"}          100                N.A.            N.A.            83                 [2](#ags312233-bib-0002){ref-type="ref"}
  153    NAR            2.6[a](#ags312233-note-0003){ref-type="fn"}          100         N.A.              N.A.       65.3                                                                                                                                    
  12     Kang           2010                                                 1998‐2005   Retrospective     146        AR           2.8 (±0.8)[a](#ags312233-note-0003){ref-type="fn"}   100                17.8            N.A.            48                 [3](#ags312233-bib-0003){ref-type="ref"}
  21     NAR            2.7 (±0.9)[a](#ags312233-note-0003){ref-type="fn"}   100         4.8               N.A.       40                                                                                                                                      
  13     Yamazaki       2010                                                 1994‐2007   Retrospective     111        AR           3.1[a](#ags312233-note-0003){ref-type="fn"}          100                46              1.8             47.5               [4](#ags312233-bib-0004){ref-type="ref"}
  98     NAR            2.7[a](#ags312233-note-0003){ref-type="fn"}          100         42                0          49.4                                                                                                                                    
  14     Kudo           2014                                                 2000‐2012   Retrospective     121        AR           3.3[a](#ags312233-note-0003){ref-type="fn"}          96                 N.A.            0.4 (total)     63                 [5](#ags312233-bib-0005){ref-type="ref"}
  112    NAR            2.6[a](#ags312233-note-0003){ref-type="fn"}          96          N.A.              69                                                                                                                                                 
  15     Okamura        2014                                                 2002‐2013   Matched cohort    64         AR           3.0 (7.0‐16.0)                                       100                21.9            0               71                 [41](#ags312233-bib-0041){ref-type="ref"}
  64     NAR            2.5 (1.0‐16.0)                                       100         18.8              0          79.7                                                                                                                                    
  16     Cucchetti      2014                                                 2001‐2010   Matched cohort    149        AR           3.0 (2.0‐4.0)                                        N.A.               N.A.            N.A.            65.8               [42](#ags312233-bib-0042){ref-type="ref"}
  149    NAR            3.0 (2.0‐4.1)                                        N.A.        N.A.              N.A.       52.9                                                                                                                                    
  17     Marubashi      2015                                                 1981‐2012   Matched cohort    329        AR           3.5 (±2.0)[a](#ags312233-note-0003){ref-type="fn"}   78.4               N.A.            N.A.            53.9 (2 y)         [43](#ags312233-bib-0043){ref-type="ref"}
  329    NAR            3.4 (±2.2)[a](#ags312233-note-0003){ref-type="fn"}   74.5        N.A.              N.A.       53.8 (2 y)                                                                                                                              
  18     Hirokawa       2015                                                 2001‐2005   Matched cohort    72         AR           3.0 (0.5‐5.0)                                        100                24              0               79                 [13](#ags312233-bib-0013){ref-type="ref"}
  72     NAR            3.0 (1.0‐5.0)                                        100         10                0          84                                                                                                                                      

Data are expressed as median (range).

AR, anatomical liver resection; N.A., not applicable; NAR, non‐anatomical liver resection.

Mean.
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The survival benefit of AR remains controversial. In retrospective studies, 5‐year overall survival has tended to be better with anatomical resection.[2](#ags312233-bib-0002){ref-type="ref"}, [6](#ags312233-bib-0006){ref-type="ref"}, [7](#ags312233-bib-0007){ref-type="ref"}, [10](#ags312233-bib-0010){ref-type="ref"}, [14](#ags312233-bib-0014){ref-type="ref"}, [44](#ags312233-bib-0044){ref-type="ref"} However, a large cohort in a national survey from Japan demonstrated that AR showed superiority in neither overall survival nor disease‐free survival compared to NAR.[12](#ags312233-bib-0012){ref-type="ref"} In subgroup analysis, superiority of AR was found only for tumors between 2 and 5 cm in diameter. Matched cohort studies showed that some populations (absence of vascular invasion, tumor diameter \>2.0 cm, degree of differentiation) were associated with better 5‐year overall survival following AR.[42](#ags312233-bib-0042){ref-type="ref"} Meta‐analysis of both 5‐year disease‐free survival and 5‐year overall survival has shown significantly better results with AR than with NAR.[15](#ags312233-bib-0015){ref-type="ref"} This result makes sense, in that HCC \<2 cm are generally effectively treated with other treatment options such as radiofrequency ablation. In cases with tumors larger than 5 cm, the high frequency of vascular invasion may impede the local treatment effects of AR. AR thus appears to have limited beneficial effects on survival in all patients. Results from further clinical studies such as large RCT are awaited to clarify which categories are suitable for AR.

3. LAPAROSCOPIC LIVER RESECTION {#ags312233-sec-0003}
===============================

Use of laparoscopic surgery for digestive procedures has increased rapidly and the approach is now mainstream in this area. Laparoscopic surgery for hepatobiliary‐pancreatic surgery has also spread quickly over the last decade, with the optimization of procedures and good selection criteria depending on tumor location contributing to improved effectiveness and safety.[46](#ags312233-bib-0046){ref-type="ref"}, [47](#ags312233-bib-0047){ref-type="ref"}, [48](#ags312233-bib-0048){ref-type="ref"} The merits of laparoscopic surgery in liver resection are thought to be the magnified view and reduced invasiveness of the operation.[49](#ags312233-bib-0049){ref-type="ref"} Compared to open liver resection, in recent reports, less blood loss from the hepatic veins during liver transection contributes to better surgical outcomes with laparoscopic surgery.[50](#ags312233-bib-0050){ref-type="ref"}, [51](#ags312233-bib-0051){ref-type="ref"}, [52](#ags312233-bib-0052){ref-type="ref"}

The history of laparoscopic liver resection is relatively long, but marked differences can be seen in procedures, patient populations and outcomes between the most recent decade and previous years. We therefore reviewed a total of 23 recent reports concerning laparoscopic liver resection from 2008, comprising 13 matched cohort studies[16](#ags312233-bib-0016){ref-type="ref"}, [17](#ags312233-bib-0017){ref-type="ref"}, [18](#ags312233-bib-0018){ref-type="ref"}, [19](#ags312233-bib-0019){ref-type="ref"}, [20](#ags312233-bib-0020){ref-type="ref"}, [21](#ags312233-bib-0021){ref-type="ref"}, [22](#ags312233-bib-0022){ref-type="ref"}, [23](#ags312233-bib-0023){ref-type="ref"} and nine retrospective studies[24](#ags312233-bib-0024){ref-type="ref"}, [25](#ags312233-bib-0025){ref-type="ref"}, [26](#ags312233-bib-0026){ref-type="ref"}, [27](#ags312233-bib-0027){ref-type="ref"}, [58](#ags312233-bib-0058){ref-type="ref"}, [59](#ags312233-bib-0059){ref-type="ref"}, [60](#ags312233-bib-0060){ref-type="ref"}, [61](#ags312233-bib-0061){ref-type="ref"} and one RCT (Table [2](#ags312233-tbl-0002){ref-type="table"}).[28](#ags312233-bib-0028){ref-type="ref"}

###### 

Laparoscopic liver resection

        First author   Year                                                 Term                                                  Study type                                           Patients                                             Disease   Procedure    Tumor size (cm)                                      Op. time (min)                                        Blood loss (mL)                                       Morbidity (%)   Mortality (%)   5‐y survival (%)   Reference no.
  ----- -------------- ---------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------- ------------ ---------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- --------------- --------------- ------------------ -------------------------------------------
  1     Topal          2008                                                 2002‐2007                                             Matched cohort                                       76                                                   N.A.      OLR          N.A.                                                 N.A.                                                  300 (5‐4000)                                          28.9            N.A.            N.A.               [16](#ags312233-bib-0016){ref-type="ref"}
  76    LLR            N.A.                                                 N.A.                                                  150 (10‐7000)                                        7.9                                                  N.A.      N.A.                                                                                                                                                                                                                             
  2     Tsinberg       2009                                                 2006‐2008                                             Retrospective                                        43                                                   Mixed     OLR          4.2 (±0.3)[a](#ags312233-note-0003){ref-type="fn"}   172 (±12)[a](#ags312233-note-0003){ref-type="fn"}     299.6 (±33.6)                                         16              0               N.A.               [24](#ags312233-bib-0024){ref-type="ref"}
  31    LLR            3.9 (±2.7)[a](#ags312233-note-0003){ref-type="fn"}   201 (±15)[a](#ags312233-note-0003){ref-type="fn"}     122.5 (±45.4)                                        13                                                   0         N.A.                                                                                                                                                                                                                             
  3     Castaing       2009                                                 1997‐2007                                             Matched cohort                                       60                                                   CRM       OLR          4.0 (8.0‐16.0)                                       N.A.                                                  N.A.                                                  N.A.            N.A.            45                 [17](#ags312233-bib-0017){ref-type="ref"}
  60    LLR            3.0 (5.0‐8.0)                                        N.A.                                                  N.A.                                                 N.A.                                                 N.A.      74                                                                                                                                                                                                                               
  4     Dagher         2009                                                 1998‐2002                                             Matched cohort                                       50                                                   Mixed     OLR          4.9 (±3.2)[a](#ags312233-note-0003){ref-type="fn"}   328 (±10.6)[a](#ags312233-note-0003){ref-type="fn"}   735.2 (±74.4)                                         34              2               N.A.               [23](#ags312233-bib-0023){ref-type="ref"}
  22    LLR            4.3 (±7.6)[a](#ags312233-note-0003){ref-type="fn"}   360 (±20.3)[a](#ags312233-note-0003){ref-type="fn"}   519.5 (±93.4)                                        9                                                    0         N.A.                                                                                                                                                                                                                             
  5     Sarpel         2009                                                 1997‐2007                                             Matched cohort                                       56                                                   HCC       OLR          4.3[a](#ags312233-note-0003){ref-type="fn"}          N.A.                                                  N.A.                                                  N.A.            N.A.            N.A.               [53](#ags312233-bib-0053){ref-type="ref"}
  20    LLR            4.3[a](#ags312233-note-0003){ref-type="fn"}          N.A.                                                  N.A.                                                 N.A.                                                 N.A.      N.A.                                                                                                                                                                                                                             
  6     Ito            2009                                                 1998‐2008                                             Matched cohort                                       65                                                   Mixed     OLR          3.4 (0.9‐13.0)                                       138[a](#ags312233-note-0003){ref-type="fn"}           200[a](#ags312233-note-0003){ref-type="fn"}           43              N.A.            56.2 (3 y)         [18](#ags312233-bib-0018){ref-type="ref"}
  65    LLR            3.3 (0.4‐14.4)                                       170[a](#ags312233-note-0003){ref-type="fn"}           100[a](#ags312233-note-0003){ref-type="fn"}          14                                                   N.A.      72.3 (3 y)                                                                                                                                                                                                                       
  7     Tranchart      2010                                                 1999‐2008                                             Matched cohort                                       42                                                   HCC       OLR          3.7[a](#ags312233-note-0003){ref-type="fn"}          221[a](#ags312233-note-0003){ref-type="fn"}           723.7[a](#ags312233-note-0003){ref-type="fn"}         40.4            2.4             37.2               [19](#ags312233-bib-0019){ref-type="ref"}
  42    LLR            3.6[a](#ags312233-note-0003){ref-type="fn"}          233[a](#ags312233-note-0003){ref-type="fn"}           364.3[a](#ags312233-note-0003){ref-type="fn"}        21.4                                                 2.4       45.6                                                                                                                                                                                                                             
  8     Vanounou       2010                                                 2002‐2008                                             Retrospective                                        29                                                   Mixed     OLR          4.1 (±3.6)                                           249[a](#ags312233-note-0003){ref-type="fn"}           N.A.                                                  24              0               N.A.               [25](#ags312233-bib-0025){ref-type="ref"}
  44    LLR            5.1 (±2.9)                                           245[a](#ags312233-note-0003){ref-type="fn"}           N.A.                                                 16                                                   0         N.A.                                                                                                                                                                                                                             
  9     Cannon         2012                                                 1995‐2010                                             Matched cohort                                       35                                                   CRM       OLR          4 (±2)[a](#ags312233-note-0003){ref-type="fn"}       N.A.                                                  392 (±324)[a](#ags312233-note-0003){ref-type="fn"}    49              0.7             37                 [20](#ags312233-bib-0020){ref-type="ref"}
  35    LLR            4 (±3)[a](#ags312233-note-0003){ref-type="fn"}       N.A.                                                  202 (±180)[a](#ags312233-note-0003){ref-type="fn"}   23                                                   0         36                                                                                                                                                                                                                               
  10    Johnson        2012                                                 2004‐2011                                             Retrospective                                        124                                                  Mixed     OLR          5.72[a](#ags312233-note-0003){ref-type="fn"}         234[a](#ags312233-note-0003){ref-type="fn"}           833 (±1008)[a](#ags312233-note-0003){ref-type="fn"}   10.4            0.8             N.A.               [58](#ags312233-bib-0058){ref-type="ref"}
  88                   LLR                                                  5.37[a](#ags312233-note-0003){ref-type="fn"}          238[a](#ags312233-note-0003){ref-type="fn"}          697 (±739)[a](#ags312233-note-0003){ref-type="fn"}   6.8       1.1          N.A.                                                                                                                                                                                                                
  11    Bhojani        2012                                                 2006‐2010                                             Retrospective                                        114                                                  Mixed     OLR          3.6 (0.8‐16.7)                                       270 (137‐500)                                         250[a](#ags312233-note-0003){ref-type="fn"}           25              0               N.A.               [59](#ags312233-bib-0059){ref-type="ref"}
  57    LLR            4.5 (0.9‐19.0)                                       240 (128‐605)                                         500[a](#ags312233-note-0003){ref-type="fn"}          39                                                   2         N.A.                                                                                                                                                                                                                             
  12    Slim           2012                                                 2008‐2011                                             Matched cohort                                       46                                                   Mixed     OLR          4.3 (1.2‐9)                                          170 (85‐315)                                          200 (50‐2000)                                         39.1            2.2             N.A.               [54](#ags312233-bib-0054){ref-type="ref"}
  46                   LLR                                                  3.2 (1.3‐8.3)                                         155 (45‐400)                                         100 (10‐800)                                         17.4      0            N.A.                                                                                                                                                                                                                
  13    Gustafson      2012                                                 2006‐2009                                             Retrospective                                        49                                                   Mixed     OLR          5.1[a](#ags312233-note-0003){ref-type="fn"}          N.A.                                                  N.A.                                                  48.8            4.1             89.8 (1 y)         [26](#ags312233-bib-0026){ref-type="ref"}
  27    LLR            2.6[a](#ags312233-note-0003){ref-type="fn"}          N.A.                                                  N.A.                                                 22.2                                                 0         85.2 (1 y)                                                                                                                                                                                                                       
  14    Kobayashi      2013                                                 1997‐2011                                             Retrospective                                        27                                                   HCC       OLR          2.0[a](#ags312233-note-0003){ref-type="fn"}          185 (120‐430)                                         450 (50‐2200)                                         0               0               62 (3 y)           [27](#ags312233-bib-0027){ref-type="ref"}
  24    LLR            2.2[a](#ags312233-note-0003){ref-type="fn"}          198 (45‐394)                                          110 (0‐1180)                                         0                                                    0         50 (3 y)                                                                                                                                                                                                                         
  15    Medbery        2014                                                 2008‐2012                                             Matched cohort                                       57                                                   Mixed     OLR          8                                                    222                                                   737                                                   44              4               N.A.               [55](#ags312233-bib-0055){ref-type="ref"}
  48    LLR            5.9                                                  175                                                   214                                                  28                                                   5         N.A.                                                                                                                                                                                                                             
  16    Komatsu        2016                                                 2006‐2014                                             Matched cohort                                       38                                                   HCC       OLR          9.2                                                  295                                                   113                                                   61              0               77.2               [21](#ags312233-bib-0021){ref-type="ref"}
  38    LLR            6.7                                                  371                                                   190                                                  32                                                   0         85.4                                                                                                                                                                                                                             
  17    Ratti          2015                                                 2011‐2015                                             Matched cohort                                       147                                                  Mixed     OLR          6                                                    200                                                   268                                                   26              0               N.A.               [56](#ags312233-bib-0056){ref-type="ref"}
  49                   LLR                                                  5                                                     259                                                  208                                                  22        2            N.A.                                                                                                                                                                                                                
  18    Nomi           2015                                                 1998‐2014                                             Retrospective                                        28                                                   Mixed     OLR          N.A.                                                 273                                                   423                                                   57              4               N.A.               [60](#ags312233-bib-0060){ref-type="ref"}
  183   LLR            N.A.                                                 279                                                   465                                                  55                                                   3         N.A.                                                                                                                                                                                                                             
  19    Yoon           2017                                                 2008‐2015                                             Matched cohort                                       115                                                  HCC       OLR          5.8[a](#ags312233-note-0003){ref-type="fn"}          202                                                   136[a](#ags312233-note-0003){ref-type="fn"}           17              0               100 (2 y)          [57](#ags312233-bib-0057){ref-type="ref"}
  37    LLR            3.1[a](#ags312233-note-0003){ref-type="fn"}          33                                                    125[a](#ags312233-note-0003){ref-type="fn"}          5                                                    0         88.8 (2 y)                                                                                                                                                                                                                       
  20    Cheung         2016                                                 2004‐2014                                             Matched cohort                                       330                                                  HCC       OLR          2.9 (0.8‐10.0)                                       255 (45‐912)                                          410 (20‐5000)                                         24.4            N.A.            67.4               [22](#ags312233-bib-0022){ref-type="ref"}
  110                  LLR                                                  2.6 (0.6‐10.0)                                        185 (50‐756)                                         150 (10‐1500)                                        10        N.A.         83.7                                                                                                                                                                                                                
  21    Xiang          2016                                                 2012‐2015                                             Retrospective                                        207                                                  HCC       OLR          6.9 (±1.5)[a](#ags312233-note-0003){ref-type="fn"}   236 (117‐466)                                         456 (50‐2000)                                         35.7            1               82.2 (3 y)         [61](#ags312233-bib-0061){ref-type="ref"}
  128   LLR            6.7 (±1.5)[a](#ags312233-note-0003){ref-type="fn"}   234 (105‐501)                                         481 (80‐3000)                                        20.3                                                 0.8       81.4 (3 y)                                                                                                                                                                                                                       
  22    Li             2017                                                 2005‐2010                                             Retrospective                                        87                                                   HCC       OLR          2.3 (±0.5)[a](#ags312233-note-0003){ref-type="fn"}   140 (±52.9)[a](#ags312233-note-0003){ref-type="fn"}   85 (10‐275)                                           73.6            N.A.            72.4               [62](#ags312233-bib-0062){ref-type="ref"}
  133   LLR            2.0 (±0.5)[a](#ags312233-note-0003){ref-type="fn"}   129 (±41.8)[a](#ags312233-note-0003){ref-type="fn"}   79 (20‐200)                                          42.9                                                 N.A.      77.4                                                                                                                                                                                                                             
  23    Fretland       2018                                                 2012‐2016                                             RCT                                                  144                                                  CRM       OLR          N.A.                                                 120 (106‐134)                                         200 (126‐273)                                         31              1               N.A.               [28](#ags312233-bib-0028){ref-type="ref"}
  129   LLR            N.A.                                                 123 (108‐138)                                         300 (224‐375)                                        19                                                   0         N.A.                                                                                                                                                                                                                             

Data are expressed as median (range).

CRM, colorectal metastasis; HCC, hepatocellular carcinoma; LLR, laparoscopic liver resection; OLR, open liver resection.

Mean.

John Wiley & Sons, Ltd

The general indications for laparoscopic resection in each study were lesions \<5 cm in diameter or systematic lobectomy. Among these, the consensus was reached that operation time was significantly longer, but blood loss was lower with laparoscopic surgery than with open liver resection.[18](#ags312233-bib-0018){ref-type="ref"}, [23](#ags312233-bib-0023){ref-type="ref"}, [24](#ags312233-bib-0024){ref-type="ref"}, [54](#ags312233-bib-0054){ref-type="ref"} Morbidity appears to be better with laparoscopic liver resection, attributable to the lower rate of infectious subcutaneous complications following reductions in the length of the skin incision.[16](#ags312233-bib-0016){ref-type="ref"}, [18](#ags312233-bib-0018){ref-type="ref"}, [19](#ags312233-bib-0019){ref-type="ref"}, [20](#ags312233-bib-0020){ref-type="ref"}, [26](#ags312233-bib-0026){ref-type="ref"}, [54](#ags312233-bib-0054){ref-type="ref"} The mortality rate with laparoscopic liver resection has now decreased and optimal safety is ensured in high‐volume centers. Among the studies examined in this report, some authors noted that survival benefits did not differ between laparoscopic and open liver resection.[19](#ags312233-bib-0019){ref-type="ref"}, [20](#ags312233-bib-0020){ref-type="ref"}, [26](#ags312233-bib-0026){ref-type="ref"}, [27](#ags312233-bib-0027){ref-type="ref"}

Recently, the results of a multi‐institutional large cohort meta‐analysis have become available.[63](#ags312233-bib-0063){ref-type="ref"} The mortality rate was only 0.4% (37 of 9527 patients), comparable to that in the Japanese national survey of open liver resection (0.4%‐0.5%).[12](#ags312233-bib-0012){ref-type="ref"} In cases of minor resection, mean intraoperative blood loss was 322 mL with laparoscopic liver resection, and 572 mL with open conventional liver resection, whereas values of 619 and 1299 mL, respectively, were seen with major liver resection. The morbidity rate was significantly better with laparoscopic liver resection than with open liver resection for both minor (13.5% vs 30.5%) or major liver resection (22.4% vs 45.6%).[63](#ags312233-bib-0063){ref-type="ref"} However, blood loss with open liver resection in these studies seemed extraordinarily high in high‐volume hepatobiliary centers.[64](#ags312233-bib-0064){ref-type="ref"}, [65](#ags312233-bib-0065){ref-type="ref"}

Development of the laparoscopic surgery procedure shows non‐inferiority even when HCC was in an unfavorable location.[66](#ags312233-bib-0066){ref-type="ref"} This Italian multicenter study mentioned that even with HCC located on the posterior segment, the procedure can be safely carried out with a conversion rate of 17.8%. In contrast, conversion as a result of unfavorable intraoperative events resulted in worse outcomes during laparoscopic liver resection.[67](#ags312233-bib-0067){ref-type="ref"} In tertiary referral centers, the conversion rate in laparoscopic surgery was 10% among 1184 major resections in 1996‐2014 and 7.8% among 2861. A history of neoadjuvant chemotherapy, previous liver resection, extent of resection and difficult location are independent predictors of the need for conversion.

Recently, results from the RCT to compare laparoscopic and open liver resection for CRM have become available.[28](#ags312233-bib-0028){ref-type="ref"} In brief, median complexity score and tumor distribution were not statistically significant, but most of the participants in this study had fewer than two tumors and median resection volume was \<100 g. Complication rate and postoperative hospital stay were significantly better in laparoscopic liver resection. Differing from the previous studies,[19](#ags312233-bib-0019){ref-type="ref"}, [24](#ags312233-bib-0024){ref-type="ref"}, [27](#ags312233-bib-0027){ref-type="ref"}, [55](#ags312233-bib-0055){ref-type="ref"} operation time was not significantly longer but intraoperative blood loss was less with laparoscopic liver resection. These results suggest that laparoscopic liver resection is catching up with conventional open liver surgery in many regards and shows superiority when carried out for optimal tumor conditions. Future prospective studies will show which conditions are more favorable for laparoscopic and conventional open liver resection.

4. ASSOCIATED LIVER PARTITION AND PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY {#ags312233-sec-0004}
=============================================================================

Insufficient volume after liver resection is one of the independent predictors for postoperative liver failure and is closely related to high mortality.[68](#ags312233-bib-0068){ref-type="ref"} The current consensus is that more than 30% of normal liver parenchyma or more than 40% of diseased liver parenchyma should be preserved when planning operations to secure patient safety. Thus, liver functional reserve and parenchyma volume should be precisely evaluated.

When the volume of remnant liver parenchyma is small, portal vein embolization (PVE) before liver resection is recommended to increase the remnant liver parenchyma.[69](#ags312233-bib-0069){ref-type="ref"} This procedure is usually adopted in right liver resection and results in an approximately 10% increase in the volume of remnant liver.[70](#ags312233-bib-0070){ref-type="ref"}, [71](#ags312233-bib-0071){ref-type="ref"} Lower limits for an indication of PVE are approximately 30% of the remnant parenchymal volume in normal liver and 40% in chronic liver disease.[72](#ags312233-bib-0072){ref-type="ref"} PVE is now widely accepted as a useful option for certain patients who may require extensive hepatectomy. When the estimated remnant liver volume after liver resection is approximately 30% of the total liver volume, ALPPS is planned to increase the volume of remnant liver.[34](#ags312233-bib-0034){ref-type="ref"} ALPPS involves simultaneous liver partition and portal vein ligation prior to the liver resection. ALPPS provides great regeneration within the short term, but indications for this procedure are now controversial because of high mortality and morbidity.

We reviewed the current series concerning ALPPS from 2012. There were 18 retrospective studies,[34](#ags312233-bib-0034){ref-type="ref"}, [73](#ags312233-bib-0073){ref-type="ref"}, [74](#ags312233-bib-0074){ref-type="ref"}, [75](#ags312233-bib-0075){ref-type="ref"}, [76](#ags312233-bib-0076){ref-type="ref"}, [77](#ags312233-bib-0077){ref-type="ref"}, [78](#ags312233-bib-0078){ref-type="ref"}, [79](#ags312233-bib-0079){ref-type="ref"} including three multicenter studies[76](#ags312233-bib-0076){ref-type="ref"}, [83](#ags312233-bib-0083){ref-type="ref"}, [84](#ags312233-bib-0084){ref-type="ref"} (Table [3](#ags312233-tbl-0003){ref-type="table"}). However, the number of participants in each study was small. We compared the current results of the five PVE papers in the same term as references.[85](#ags312233-bib-0085){ref-type="ref"}, [86](#ags312233-bib-0086){ref-type="ref"}, [87](#ags312233-bib-0087){ref-type="ref"}, [88](#ags312233-bib-0088){ref-type="ref"}, [89](#ags312233-bib-0089){ref-type="ref"} The number of patients in PVE groups was sufficient to assess the outcomes. The most common current indication for ALPPS was multiple CRM, which suggests that most patients have good liver functional reserve. In contrast, the common indications for PVE were Klatskin tumor, HCC and colorectal metastasis. Rates of increase in liver volume were surprisingly different. With the ALPPS procedure, median rate of increase in remnant liver parenchyma over the first 2 weeks ranged from 48% to 113.1%, compared to 7.4% to 12% with PVE.

###### 

Associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) and portal vein embolization (PVE)

       First author          Year   Term        No. of patients   Procedure   Study type                    Disease (%)       Increased liver volume (%)                            Blood loss in liver partition (mL)                  Time from treatment to assessment (days)   Morbidity (%)   Mortality (%)   Reference no.
  ---- --------------------- ------ ----------- ----------------- ----------- ----------------------------- ----------------- ----------------------------------------------------- --------------------------------------------------- ------------------------------------------ --------------- --------------- -------------------------------------------
  1    Schnitzbauer          2012   2007‐2011   25                ALLPS       Retrospective                 CRM (56)          74 (21 to 192)                                        320 (150‐7500)                                      9                                          64              12              [34](#ags312233-bib-0034){ref-type="ref"}
  2    Torres                2013   2011‐2012   39                ALLPS       Retrospective                 CRM (82)          83 (47 to 212)                                        N.A.                                                14                                         59              12.8            [73](#ags312233-bib-0073){ref-type="ref"}
  3    Nadalin               2014   2010‐2013   15                ALLPS       Retrospective                 CRM (33)          87 (23.8 to 161)                                      N.A.                                                13                                         67              29              [74](#ags312233-bib-0074){ref-type="ref"}
  4    Robles                2014   2011‐2013   22                ALLPS       Retrospective                 CRM (77.3)        61 (33 to 189)                                        100 (0‐900)                                         7                                          63              9               [75](#ags312233-bib-0075){ref-type="ref"}
  5    Schadde               2014   2012‐2013   202               ALLPS       Retrospective (multicenter)   CRM (58)          86[a](#ags312233-note-0010){ref-type="fn"}            N.A.                                                10                                         40              9               [76](#ags312233-bib-0076){ref-type="ref"}
  6    Kremer                2015   2011‐2014   19                ALLPS       Retrospective                 CRM               74 (`±`35)[a](#ags312233-note-0010){ref-type="fn"}    1380 (200‐700)                                      8                                          68              16              [77](#ags312233-bib-0077){ref-type="ref"}
  7    Hernandez‐Alejandro   2015   2012‐2013   14                ALLPS       Retrospective                 CRM (80.6)        93 (±28)[a](#ags312233-note-0010){ref-type="fn"}      725 (±85)[a](#ags312233-note-0010){ref-type="fn"}   8                                          36              0               [78](#ags312233-bib-0078){ref-type="ref"}
  8    Truant                2015   2011‐2013   62                ALLPS       Retrospective                 CRM (63)          48 (−15.3 to 192)                                     494 (±35)[a](#ags312233-note-0010){ref-type="fn"}   8                                          80.6            12.9            [79](#ags312233-bib-0079){ref-type="ref"}
  9    Alvarez               2015   2011‐2014   30                ALLPS       Retrospective                 CRM (64)          89.7 (21 to 287)                                      N.A.                                                6                                          53              6.6             [80](#ags312233-bib-0080){ref-type="ref"}
  10   Lang                  2015   2007‐2014   16                ALLPS       Retrospective                 CRM (56.3)        113.1 (38.6 to 207.7)                                 N.A.                                                9                                          64              12.5            [81](#ags312233-bib-0081){ref-type="ref"}
  11   Chan                  2016   2013‐2015   17                ALLPS       Retrospective                 HCC               48.7[a](#ags312233-note-0010){ref-type="fn"}          500 (100‐2000)                                      8                                          15.3            7.7             [82](#ags312233-bib-0082){ref-type="ref"}
  12   Røsok                 2016   2012‐2014   36                ALLPS       Retrospective (multicenter)   CRM (69.4)        67 (−17 to 238)                                       675 (150‐5600)                                      6                                          92              0               [83](#ags312233-bib-0083){ref-type="ref"}
  13   Serenari              2016   2012‐2014   50                ALLPS       Retrospective (multicenter)   CRM (44)          N.A.                                                  N.A.                                                N.A.                                       54              20              [84](#ags312233-bib-0084){ref-type="ref"}
  14   Sakuhara              2012   1999‐2009   143               PVE         Retrospective                 Klatskin (47.6)   10.7 (±6.7)[a](#ags312233-note-0010){ref-type="fn"}   --                                                  17                                         6.3             0               [85](#ags312233-bib-0085){ref-type="ref"}
  15   Leung                 2014   1999‐2012   153               PVE         Retrospective                 CRM (89.5)        9.64 (6.75 to 12.36)                                  --                                                  27                                         56.8            1.3             [86](#ags312233-bib-0086){ref-type="ref"}
  16   Shindoh               2014   1995‐2012   358               PVE         Retrospective                 CRM (60.6)        N.A.                                                  --                                                  32                                         25.8            3.8             [87](#ags312233-bib-0087){ref-type="ref"}
  17   Sofue                 2014   2007‐2011   83                PVE         Retrospective                 Klatzkin (44.6)   12 (5 to 8)[a](#ags312233-note-0010){ref-type="fn"}   --                                                  17                                         5               0               [88](#ags312233-bib-0088){ref-type="ref"}
  18   Cazejust              2015   2009‐2013   63                PVE         Retrospective                 HCC (63.3)        11 (±7)[a](#ags312233-note-0010){ref-type="fn"}       --                                                  24                                         11.1            N.A.            [89](#ags312233-bib-0089){ref-type="ref"}

Data are expressed as median (range).

CRM, colorectal metastasis; HCC, hepatocellular carcinoma.

Mean.

Transfusion rate (%).

John Wiley & Sons, Ltd

The most concerning problems in ALPPS are morbidity and mortality. Morbidity rate in ALPPS ranged from 15.3% to 92%, and mortality rate ranged from 0% to 29%. Severe complications appeared to be frequent after this procedure. In the first ALPPS procedures, intraoperative blood loss to partition the liver parenchyma was too high, ranging from 100 to 725 mL. Meta‐analysis confirmed the results of operation‐related outcomes.[90](#ags312233-bib-0090){ref-type="ref"}, [91](#ags312233-bib-0091){ref-type="ref"}, [92](#ags312233-bib-0092){ref-type="ref"} This procedure is therefore considered to be under development and modifications of the procedure and revision of its indications will be required in order to improve safety.

To obtain safe procedures, some modifications to the original ALPPS have been advocated including an anterior approach with complete parenchymal division down to the IVC, an in situ split using an anterior approach followed by PVE by interventional radiology, and partial transection using the anterior approach.[36](#ags312233-bib-0036){ref-type="ref"}, [37](#ags312233-bib-0037){ref-type="ref"}, [38](#ags312233-bib-0038){ref-type="ref"}, [39](#ags312233-bib-0039){ref-type="ref"}, [93](#ags312233-bib-0093){ref-type="ref"} These modified techniques have contributed to decreases in the mortality and morbidity of ALPPS. Recently, an analysis of the international ALPPS registry cautioned against overuse of ALPPS.[35](#ags312233-bib-0035){ref-type="ref"} One‐third of ALPPS procedures for CRM were carried out without objective indications. Thus, keeping to strict indications for ALPPS would mean the procedure is done only when tri‐segmentectomy is needed for the purposes of addressing a wide tumor distribution.

5. CHEMOTHERAPY‐ASSOCIATED LIVER DAMAGE {#ags312233-sec-0005}
=======================================

Systemic chemotherapy has no doubt changed the current strategy for patients with advanced CRM. The prognosis has improved significantly on the basis of current combination chemotherapies (5‐fluorouracil, and oxaliplatin or irinotecan) with humanized monoclonal antibodies. As a result, liver resection provides potential "cure" in 10%‐30% of patients with initially unresectable CRM.[29](#ags312233-bib-0029){ref-type="ref"} However, giving long‐term chemotherapy induces chronic liver damage and is considered harmful for the prospects of future liver resection. Oxaliplatin‐induced liver damage is termed "blue liver," pathologically appearing as sinusoidal obstruction[29](#ags312233-bib-0029){ref-type="ref"}, [30](#ags312233-bib-0030){ref-type="ref"}, [31](#ags312233-bib-0031){ref-type="ref"}, [94](#ags312233-bib-0094){ref-type="ref"} and nodular regenerative hyperplasia in the liver parenchyma.[33](#ags312233-bib-0033){ref-type="ref"} Irinotecan‐induced liver damage is called "yellow liver," representing steatosis or steatohepatitis in liver parenchyma.[94](#ags312233-bib-0094){ref-type="ref"}, [95](#ags312233-bib-0095){ref-type="ref"} The parenchymal damage from chemotherapy negatively influences the postoperative outcomes. However, the pathophysiological background to such damage remains insufficiently understood.

5.1. Sinusoidal injury {#ags312233-sec-0006}
----------------------

Sinusoidal obstruction syndrome (SOS) was first described in patients given pyrrolizidine alkaloids.[96](#ags312233-bib-0096){ref-type="ref"} The key pathological feature is sinusoidal dilatation with hepatocyte atrophy. SOS is categorized into four grades (0‐3) according to pathological changes, depending on the duration of chemotherapy. SOS progresses to perisinusoidal fibrosis and nodular regenerative hyperplasia. Oxaliplatin increases the risk of developing sinusoidal injury by approximately 2.22‐ to 4.36‐fold when patients receive more than six cycles of chemotherapy.[96](#ags312233-bib-0096){ref-type="ref"}

5.2. Hepatic steatosis and hepatitis {#ags312233-sec-0007}
------------------------------------

Liver steatosis and steatohepatitis induced by chemotherapy are thought to be mainly induced by irinotecan regimens. Postoperative risks appear to differ between steatosis and steatohepatitis. The pathological features vary from simple steatosis to steatohepatitis, hepatic fibrosis and cirrhosis, depending on the duration of parenchymal injury. The most widely used grading system was proposed by Kleiner et al, which categorizes features into four grades depending on the degree of steatosis (\<5%, 5%‐33%, 33%‐66% and \>66%).[97](#ags312233-bib-0097){ref-type="ref"} Steatohepatitis progresses to hepatic fibrosis and cirrhosis. Some reports have described high‐grade steatosis as associated with a threefold increase in postoperative mortality.[98](#ags312233-bib-0098){ref-type="ref"} However, whether hepatic steatosis alone increases the risk of postoperative mortality remains controversial. In contrast, steatohepatitis is known to increase the risk of postoperative mortality when the patient receives more than 7.5 cycles of chemotherapy. Body mass index is one surrogate marker for high risk of hepatic steatohepatitis.[99](#ags312233-bib-0099){ref-type="ref"}

We reviewed 11 papers to assess the relationship between postoperative morbidity and perioperative chemotherapy from 2003 (Table [4](#ags312233-tbl-0004){ref-type="table"}). These included 10 retrospective studies[30](#ags312233-bib-0030){ref-type="ref"}, [31](#ags312233-bib-0031){ref-type="ref"}, [32](#ags312233-bib-0032){ref-type="ref"}, [33](#ags312233-bib-0033){ref-type="ref"}, [94](#ags312233-bib-0094){ref-type="ref"}, [100](#ags312233-bib-0100){ref-type="ref"}, [101](#ags312233-bib-0101){ref-type="ref"}, [102](#ags312233-bib-0102){ref-type="ref"} and one RCT.[29](#ags312233-bib-0029){ref-type="ref"} The number of participants in each study varied. Most patients in the chemotherapy group were given systemic preoperative chemotherapy for metastasis from colorectal cancer. The data suggested that irinotecan‐based chemotherapy was closely associated with development of steatohepatitis.[105](#ags312233-bib-0105){ref-type="ref"} Presence of steatohepatitis has been shown to increase postoperative morbidity and mortality in non‐alcoholic steatohepatitis (NASH) patients.[106](#ags312233-bib-0106){ref-type="ref"} The pathological feature of chemotherapy‐induced liver damage resembles that in NASH patients. Some authors have cautioned that long‐term chemotherapy‐induced steatohepatitis is thus a risk for postoperative mortality. However, the optimal method for estimating liver functional reserve and how far liver resection can be safely carried out remains unconfirmed. Interruption of chemotherapy is reported to improve liver function (indocyanine green \[ICG\] retention rate at 15 minutes value from 17.7% to 11.6%) within 4 weeks.[107](#ags312233-bib-0107){ref-type="ref"} Therefore, estimation by ICG may be of value to estimate chemotherapy‐induced liver damage.

###### 

Chemotherapy‐induced perioperative risk

        First author                                     Year                                                         Term        Study type                                               Patients                     Setting                                           Tumor diameter (cm)                                          Single tumor (%)   Blood loss (mL)                                        Morbidity (%)               Mortality (%)   DFS          5SU    Reference no.
  ----- ------------------------------------------------ ------------------------------------------------------------ ----------- -------------------------------------------------------- ---------------------------- ------------------------------------------------- ------------------------------------------------------------ ------------------ ------------------------------------------------------ --------------------------- --------------- ------------ ------ --------------------------------------------
  1     Parikh                                           2003                                                         1997‐2002   Retrospective                                            34                           Preoperative chemo (CPT‐based)                    2.0 (0.8‐6.5)                                                60                 500[a](#ags312233-note-0014){ref-type="fn"}            29                          0               N.A.         N.A.   [33](#ags312233-bib-0033){ref-type="ref"}
  47    Surgery alone                                    4.3 (0.9‐10.3)                                               27          425[a](#ags312233-note-0014){ref-type="fn"}              49                           0                                                 N.A.                                                         N.A.                                                                                                                                      
  2     Fernandez                                        2005                                                         2001‐2003   Retrospective                                            14                           Preoperative chemo (OX‐ or CPT‐based) + surgery   N.A.                                                         N.A.               N.A.                                                   N.A.                        0               N.A.         N.A.   [94](#ags312233-bib-0094){ref-type="ref"}
  14    Surgery alone                                    N.A.                                                         N.A.        N.A.                                                     N.A.                         0                                                 N.A.                                                         N.A.                                                                                                                                      
  3     Karoui                                           2006                                                         1998‐2002   Retrospective                                            45                           Preoperative chemo + major surgery                3.0 (±1.7)[a](#ags312233-note-0014){ref-type="fn"}           N.A.               44.5[b](#ags312233-note-0015){ref-type="fn"}           37.8                        0               N.A.         N.A.   [100](#ags312233-bib-0100){ref-type="ref"}
  22    Major surgery                                    2.6 (±2.3)[a](#ags312233-note-0014){ref-type="fn"}           N.A.        45.5[b](#ags312233-note-0015){ref-type="fn"}             13.6                         0                                                 N.A.                                                         N.A.                                                                                                                                      
  4     Sahajpal                                         2007                                                         2001‐2003   Retrospective                                            53                           Preoperative chemo + surgery                      4.5                                                          N.A.               1242[a](#ags312233-note-0014){ref-type="fn"}           39.6                        0               N.A.         N.A.   [101](#ags312233-bib-0101){ref-type="ref"}
  43    Surgery alone                                    5.8                                                          N.A.        1245[a](#ags312233-note-0014){ref-type="fn"}             51.2                         0                                                 N.A.                                                         N.A.                                                                                                                                      
  5     Nordlinger                                       2008                                                         2000‐2004   RCT                                                      182                          Perioperative chemo (OX‐based)                    N.A.                                                         51                 N.A.                                                   25                          1               28.1 (3 y)   N.A.   [29](#ags312233-bib-0029){ref-type="ref"}
  182   Surgery alone                                    N.A.                                                         52          N.A.                                                     16                           1                                                 36.2 (3 y)                                                   N.A.                                                                                                                                      
  6     Hubert                                           2010                                                         2000‐2006   Retrospective                                            72                           Perioperative chemo (OX‐based)                    N.A.                                                         47                 225 (150‐1600)                                         57.3                        0               N.A.         N.A.   [30](#ags312233-bib-0030){ref-type="ref"}
  18    Surgery alone                                    N.A.                                                         73          600 (150‐4700)[a](#ags312233-note-0014){ref-type="fn"}   50                           3                                                 N.A.                                                         N.A.                                                                                                                                      
  7     Kishi                                            2010                                                         1999‐2007   Retrospective                                            157                          Preoperative short‐term chemo + surgery           2.1 (0.4‐14.0)                                               36                 230 (10‐1500)                                          3.8 (liver insufficiency)   N.A.            N.A.         N.A.   [102](#ags312233-bib-0102){ref-type="ref"}
  62    Preoperative chemo long‐term chemo + surgery     2.7 (0.4‐10.5)                                               31          200 (20‐3100)                                            11.3 (liver insufficiency)   N.A.                                              N.A.                                                         N.A.                                                                                                                                      
  8     Soubrane                                         2010                                                         1998‐2007   Retrospective                                            13                           Preoperative chemo (SOS low‐grade) + surgery      6.3 (total length)[a](#ags312233-note-0014){ref-type="fn"}   N.A.               483 (±328)[a](#ags312233-note-0014){ref-type="fn"}     23.1                        0               N.A.         N.A.   [1](#ags312233-bib-0001){ref-type="ref"}
  38    Preoperative chemo (SOS high‐grade) + surgery    7.9 (total length)[a](#ags312233-note-0014){ref-type="fn"}   N.A.        880 (±960)[a](#ags312233-note-0014){ref-type="fn"}       26.3                         5.3                                               N.A.                                                         N.A.                                                                                                                                      
  9     Pessaux                                          2010                                                         200‐2009    Retrospective                                            26                           Preoperative chemo (Cmab) + surgery               4.8[a](#ags312233-note-0014){ref-type="fn"}                  88.5               1019 (±1597)[a](#ags312233-note-0014){ref-type="fn"}   34.6                        0               N.A.         N.A.   [103](#ags312233-bib-0103){ref-type="ref"}
  26    Preoperative chemo (without Cmab) + surgery      4.3[a](#ags312233-note-0014){ref-type="fn"}                  88.5        708 (±452)[a](#ags312233-note-0014){ref-type="fn"}       30.8                         0                                                 N.A.                                                         N.A.                                                                                                                                      
  10    Makowiec                                         2011                                                         2001‐207    Retrospective                                            68                           Preoperative chemo + surgery                      N.A.                                                         N.A.               N.A.                                                   50                          6               N.A.         N.A.   [104](#ags312233-bib-0104){ref-type="ref"}
  34    Surgery alone                                    N.A.                                                         N.A.        N.A.                                                     44                           2                                                 N.A.                                                         N.A.                                                                                                                                      
  11    van der Pool                                     2012                                                         2003‐2008   Retrospective                                            53                           Preoperative chemo (OX‐based) + surgery           3.5 (1‐7)                                                    N.A.               32[b](#ags312233-note-0015){ref-type="fn"}             32.1                        N.A.            32 (3 y)     N.A.   [32](#ags312233-bib-0032){ref-type="ref"}
  51    Preoperative chemo (OX‐based + Bmab) + surgery   2.8 (1‐18)                                                   N.A.        29[b](#ags312233-note-0015){ref-type="fn"}               25.5                         N.A.                                              23 (3 y)                                                     N.A.                                                                                                                                      

Data are expressed as median (range).

CPT, irinotecan; DFS, disease‐free survival; OX, oxaliplatin; RCT, randomized controlled trial; SOS, sinusoidal occlusion syndrome.
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Whether preoperative chemotherapy increases intraoperative blood loss is a controversial issue. Intraoperative blood loss is significantly greater in pathological high‐grade SOS than in low‐grade SOS.[31](#ags312233-bib-0031){ref-type="ref"} This difference may reflect the hepatic venous pressure gradient and parenchymal stiffness, and the increasing rate of SOS is associated with morbidity after liver resection. Rate of increase in splenic volume and decrease in platelet count are predictive of SOS.[108](#ags312233-bib-0108){ref-type="ref"}, [109](#ags312233-bib-0109){ref-type="ref"}, [110](#ags312233-bib-0110){ref-type="ref"}, [111](#ags312233-bib-0111){ref-type="ref"} Reportedly, 75% of patients who received adjuvant chemotherapy had increased splenic volume and 40% of patients did not recover after discontinuation of chemotherapy.[99](#ags312233-bib-0099){ref-type="ref"}, [111](#ags312233-bib-0111){ref-type="ref"} Giving bevacizumab in combination with systemic chemotherapy reduces the occurrence of SOS.[112](#ags312233-bib-0112){ref-type="ref"} However, the duration and extent to which liver function can recover remains unclear.

6. CONCLUSION {#ags312233-sec-0008}
=============

Liver resection has gained wide use with more precise preoperative evaluation of hepatic functional reserve and tumor status. We now have the Japanese treatment algorithm to aid in decision‐making for the surgical treatment of HCC, backed up by robust evidence.[113](#ags312233-bib-0113){ref-type="ref"} Anatomical resection for HCC is a more complex procedure that results in greater intraoperative blood loss and longer operation time. Overall survival from HCC is multifactorial, but a significant positive impact on survival has been observed in anatomical resection. However, no RCT have determined whether anatomical resection is an essential technique for HCC. The results of our ongoing RCT might allow the establishment of optimized procedures.

There is currently no doubt that laparoscopic liver surgery offers comparable mortality to open liver resection when the optimal location and procedure are selected.[22](#ags312233-bib-0022){ref-type="ref"}, [28](#ags312233-bib-0028){ref-type="ref"}, [57](#ags312233-bib-0057){ref-type="ref"}, [61](#ags312233-bib-0061){ref-type="ref"}, [62](#ags312233-bib-0062){ref-type="ref"} Laparoscopic liver resection is technically demanding and requires technical command of both liver and laparoscopic surgery. Recently, consensus guidelines to determine suitable tumor location and optimal procedure for laparoscopic liver resection have been developed. A pre‐registration system has also been available since 2015 to ensure safety and to maintain the quality of laparoscopic liver resection.[46](#ags312233-bib-0046){ref-type="ref"}, [114](#ags312233-bib-0114){ref-type="ref"}, [115](#ags312233-bib-0115){ref-type="ref"}

High morbidity and mortality rates remain the most critical problem in ALPPS, which is now a widely accepted option for "marginal resectable" patients with Klatskin tumor or multiple CRM. However, we must keep in mind that patients with primary unresectable CRM experience a high rate of recurrence and receive long‐term chemotherapy. Thus, careful evaluation for chemotherapy‐induced liver injury is needed to maintain quality for ALPPS. Use of a risk score for ALPPS and further refinement of the indications for ALPPS are warranted.[35](#ags312233-bib-0035){ref-type="ref"}, [116](#ags312233-bib-0116){ref-type="ref"} To overcome these problems, a pre‐registration system is now available and may provide a way to obtain safer indications for ALPPS.[117](#ags312233-bib-0117){ref-type="ref"}

Current chemotherapies are obviously powerful, but are closely associated with liver injury, which is regimen‐specific.[118](#ags312233-bib-0118){ref-type="ref"} We should keep in mind that preoperative long‐term chemotherapy is a risk factor for liver injury. Thus, in cases of major liver resection in patients who have received long‐term chemotherapy, precise evaluation of liver functional reserve and volume should be carried out.

We have presented topics on the current treatment strategies for liver cancers, showing that surgery has the power to dramatically improve prognosis and the primary option of choice. It is important to take into account the balance between tumor distribution and difficulty of operation. Consideration of the advantages of techniques and treatment effects is important and the method of the operation should not be the purpose of the treatment. Safety is the first priority in surgical treatment and should be refined using high‐level evidence as it becomes available.
